SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT04150042
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitamin C with autologous hematopoietic stem cell infusion. A dose-escalation schedule is being employed for the vitamin C.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pancreatic Adenocarcinoma Metastatic
- BRCA1 Mutation
- BRCA2 Mutation
- Pancreatic Acinar Cell Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
- Breast Cancer Metastatic
- Breast Cancer Stage IV
- Pancreatic Cancer Stage IV
- HER2-negative Breast Cancer
- HER2 Negative Breast Carcinoma
- Adenocarcinoma of the Breast
- PALB2 Gene Mutation
- Pancreas Cancer, Metastatic
- Pancreas Cancer, Recurrent
- Pancreas Cancer
- Stage IV Pancreatic Cancer
- Stage 4 Pancreatic Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- General Oncology, Inc.
- Last updated on ClinicalTrials.gov
- January 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.